COVID-19 Vaccine Stocks: Is Inovio Still In Play?
When it comes to psychedelics, today’s article notes that “While this industry is still in its early stages, the promising pInovio Pharmaceuticals went from being…
COVID-19
Focus In The Biotech Sector Could Soon Turn To These Therapeutic Areas And Companies
While vaccine makers have gotten most of the attention in the biotech sector over the past year, the author of today’s article advises that other…
A Strong Product Pipeline, Solid Upside And Attractive Valuation Could Make This Biotech A Buy
With nine FDA-approved products and more than 30 product candidates in clinical development – including a potential COVID-19 therapeutic – the biotechnology company featured in…
Will Biotech Buck The Historical Trend This March? (And Where Will Biotech Go After 2021?)
Historically, January and February tend to be very strong months for biotech, while March tends to be very weak. But, with COVID-19 continuing to bear…
With A Potential Solution To One Of The Biggest COVID Vaccine Problems, Could This Stock Be The Next Moderna?
This previously little-known immunotherapy stock recently saw its shares soar nearly 249% — and its market value surge from $300 million to more than $1…
Small-Caps’ Big Rebound – And Further Move Higher?
After crashing in March as the novel coronavirus became a global crisis dramatically affecting everyday life, small-cap stocks have staged a remarkable rebound. And while…
With Coronavirus Vaccines Still In Development, These 3 Stocks Are Poised To Soar This Year (With Some Risk)
In 2021, “The big stories…could come from vaccines that haven’t made it to market yet. It’s possible that the stocks of the companies developing these…
5 Health Care Stocks That Could Be Top Performers In 2021
Today’s article highlights five health care stocks that analysts believe could be top performers in 2021, with the author advising that “While certainly not as…
With A Focus On Genomics, This Lesser-Known ETF Is Outperforming – And Now May Be The Time To Buy
The lesser-known ETF discussed in today’s article is already beating the market – up 185% year to date – and the author believes it will…
3 Biotech Stocks Flying High In The Mid-Cap “Sweet Spot”
In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including…